Braveheart Bio, Inc.
BRVE
Positions held
Your positionsBRVE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Braveheart Bio, Inc. operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, attracting significant investor interest.
- Braveheart Bio has a market capitalization of approximately $1.78 billion, indicating strong investor confidence in its future prospects.
- The company has a current ratio of 13.628, suggesting it is well-positioned to meet its short-term liabilities.
- The company has a forward P/E ratio of -9.94, indicating that it is currently unprofitable and may face challenges in generating positive earnings in the near term.
- Braveheart Bio reported a net income of -14.988 million in Q2 2026, highlighting ongoing financial losses.
- The company's operating income was -15.882 million in Q2 2026, reflecting difficulties in managing operational costs.
Fundamentals
| Market cap | $1.72B | Enterprise value | $1.65B | Trailing P/E | — | Forward P/E | -9.59 |
| PEG | — | Price / book | -1.50 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.00 |
| Current ratio | 13.63 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $45.25 |
| 52w high | $32.00 | 52w low | $17.86 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.0M | — | $0.0M | — |
| Op margin | — | — | — | — |
| Net income | -$15.0M | — | -$0.4M | — |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$15.9M | — | -$0.0M | — |
Yearly (6y)
| 2025 | |
|---|---|
| Revenue | — |
| Op margin | — |
| Net income | — |
| Gross margin | — |
| Gross profit | — |
| Operating income | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-16 · Braveheart Bio to Participate in Stifel Cardiometabolic Forum
2026-09-08 · Braveheart Bio Q2 Net Loss Widens
2026-09-08 · Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-09-08 · The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
2026-09-01 · Braveheart Bio to Participate in Cantor Global Healthcare Conference
2026-08-31 · Insiders Are Betting Big on These 3 Healthcare Stocks
2026-08-31 · Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
2026-08-31 · Jefferies starts biopharma firm Braveheart at Buy after IPO
2026-08-11 · Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO
Price (daily)
Full chart · RSI · MACD · patterns